CCA
NVO

Cravens & Co Advisors’s Novo Nordisk NVO Stock Holding History

Cravens & Co Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Sell
23,681
-4,993
-17% -$215K 0.76% 32
2026
Q1 		$1.05M Buy
28,674
+19,588
+216% +$928K 0.68% 31
2025
Q4 		$542K Sell
9,086
-7,367
-45% -$377K 0.35% 44
2025
Q3 		$913K Buy
16,453
+7,243
+79% +$424K 0.62% 36
2025
Q2 		$636K Buy
9,210
+177
+2% +$12K 0.47% 38
2025
Q1 		$627K Buy
9,033
+1,210
+15% +$99.9K 0.49% 37
2024
Q4 		$673K Sell
7,823
-274
-3% -$29.6K 0.51% 38
2024
Q3 		$964K Buy
8,097
+128
+2% +$17.1K 0.74% 31
2024
Q2 		$1.14M Sell
7,969
-281
-3% -$37.2K 0.84% 25
2024
Q1 		$1.06M Buy
8,250
+85
+1% +$10.1K 0.88% 25
2023
Q4 		$845K Sell
8,165
-23
-0.3% -$2.27K 0.73% 31
2023
Q3 		$745K Buy
8,188
+72
+0.9% +$6.34K 0.7% 34
2023
Q2 		$657K Sell
8,116
-2,502
-24% -$204K 0.6% 42
2023
Q1 		$845K Buy
10,618
+6
+0.1% +$425 0.79% 25
2022
Q4 		$718K Buy
+10,612
New +$622K 0.66% 30

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Cravens & Co Advisors's NVO Position: Q2 2026 in Review

Cravens & Co Advisors reduced its Novo Nordisk (NVO) stake by 17% in Q2 2026, selling an estimated $215K and leaving 23,681 shares worth $1.14M. The position accounts for 0.76% of the portfolio, ranked #32.

Cravens & Co Advisors first reported a position in NVO in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.14M in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Cravens & Co Advisors held 23,681 shares of Novo Nordisk worth $1.14M as of Q2 2026.
  • Cravens & Co Advisors sold 4,993 Novo Nordisk shares in Q2 2026, an estimated $215K.
  • Novo Nordisk made up 0.76% of Cravens & Co Advisors's portfolio in Q2 2026, its #32 holding.
  • Cravens & Co Advisors first reported a position in Novo Nordisk in Q4 2022 and has held it in 15 quarters since.
  • Cravens & Co Advisors's Novo Nordisk position peaked at $1.14M in Q2 2024.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Cravens & Co Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.